Literature DB >> 21906628

Resistance to maribavir is associated with the exclusion of pUL27 from nucleoli during human cytomegalovirus infection.

Morgan Hakki1, Coyne Drummond, Benjamin Houser, Gail Marousek, Sunwen Chou.   

Abstract

Select mutations in the human cytomegalovirus (HCMV) gene UL27 confer low-grade resistance to the HCMV UL97 kinase inhibitor maribavir (MBV). It has been reported that the 608-amino acid UL27 gene product (pUL27) normally localizes to cell nuclei and nucleoli, whereas its truncation at codon 415, as found in a MBV-resistant mutant, results in cytoplasmic localization. We now show that in the context of full-length pUL27, diverse single amino acid substitutions associated with MBV resistance result in loss of its nucleolar localization when visualized after transient transfection, whereas substitutions representing normal interstrain polymorphism had no such effect. The same differences in localization were observed during a complete infection cycle with recombinant HCMV strains over-expressing full-length fluorescent pUL27 variants. Nested UL27 C-terminal truncation expression plasmids showed that amino acids 596-599 were required for the nucleolar localization of pUL27. These results indicate that the loss of a nucleolar function of pUL27 may contribute to MBV resistance, and that the nucleolar localization of pUL27 during HCMV infection depends not only on a carboxy-terminal domain but also on a property of pUL27 that is affected by MBV-resistant mutations, such as an interaction with component(s) of the nucleolus.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21906628      PMCID: PMC3232008          DOI: 10.1016/j.antiviral.2011.08.019

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  34 in total

1.  Recombinant phenotyping of cytomegalovirus UL97 kinase sequence variants for ganciclovir resistance.

Authors:  Sunwen Chou
Journal:  Antimicrob Agents Chemother       Date:  2010-04-12       Impact factor: 5.191

Review 2.  Nucleolar targeting: the hub of the matter.

Authors:  Edward Emmott; Julian A Hiscox
Journal:  EMBO Rep       Date:  2009-02-20       Impact factor: 8.807

3.  Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir.

Authors:  Sunwen Chou
Journal:  Antimicrob Agents Chemother       Date:  2008-11-03       Impact factor: 5.191

4.  En passant mutagenesis: a two step markerless red recombination system.

Authors:  B Karsten Tischer; Gregory A Smith; Nikolaus Osterrieder
Journal:  Methods Mol Biol       Date:  2010

5.  The human cytomegalovirus IE2 and UL112-113 proteins accumulate in viral DNA replication compartments that initiate from the periphery of promyelocytic leukemia protein-associated nuclear bodies (PODs or ND10).

Authors:  J H Ahn; W J Jang; G S Hayward
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

Review 6.  Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir.

Authors:  Sunwen Chou
Journal:  Rev Med Virol       Date:  2008 Jul-Aug       Impact factor: 6.989

Review 7.  Signaling to p53: ribosomal proteins find their way.

Authors:  Yanping Zhang; Hua Lu
Journal:  Cancer Cell       Date:  2009-11-06       Impact factor: 31.743

8.  Nucleolar disruption impairs Kaposi's sarcoma-associated herpesvirus ORF57-mediated nuclear export of intronless viral mRNAs.

Authors:  James R Boyne; Adrian Whitehouse
Journal:  FEBS Lett       Date:  2009-10-20       Impact factor: 4.124

Review 9.  In search of nonribosomal nucleolar protein function and regulation.

Authors:  Thoru Pederson; Robert Y L Tsai
Journal:  J Cell Biol       Date:  2009-03-16       Impact factor: 10.539

Review 10.  Involvement of the nucleolus in replication of human viruses.

Authors:  Anna Greco
Journal:  Rev Med Virol       Date:  2009-07       Impact factor: 6.989

View more
  6 in total

1.  Effects on maribavir susceptibility of cytomegalovirus UL97 kinase ATP binding region mutations detected after drug exposure in vitro and in vivo.

Authors:  Sunwen Chou; Morgan Hakki; Stephen Villano
Journal:  Antiviral Res       Date:  2012-06-01       Impact factor: 5.970

Review 2.  Progress in the development of new therapies for herpesvirus infections.

Authors:  Nathan B Price; Mark N Prichard
Journal:  Curr Opin Virol       Date:  2011-12       Impact factor: 7.090

3.  Cytomegalovirus Late Protein pUL31 Alters Pre-rRNA Expression and Nuclear Organization during Infection.

Authors:  Kristen N Westdorp; Andrea Sand; Nathaniel J Moorman; Scott S Terhune
Journal:  J Virol       Date:  2017-08-24       Impact factor: 5.103

4.  Antagonistic Relationship between Human Cytomegalovirus pUL27 and pUL97 Activities during Infection.

Authors:  Tarin M Bigley; Justin M Reitsma; Scott S Terhune
Journal:  J Virol       Date:  2015-07-29       Impact factor: 5.103

5.  Novel method based on "en passant" mutagenesis coupled with a gaussia luciferase reporter assay for studying the combined effects of human cytomegalovirus mutations.

Authors:  Emilien Drouot; Jocelyne Piret; Guy Boivin
Journal:  J Clin Microbiol       Date:  2013-07-17       Impact factor: 5.948

6.  Detection of Low Frequency Multi-Drug Resistance and Novel Putative Maribavir Resistance in Immunocompromised Pediatric Patients with Cytomegalovirus.

Authors:  Charlotte J Houldcroft; Josephine M Bryant; Daniel P Depledge; Ben K Margetts; Jacob Simmonds; Stephanos Nicolaou; Helena J Tutill; Rachel Williams; Austen J J Worth; Stephen D Marks; Paul Veys; Elizabeth Whittaker; Judith Breuer
Journal:  Front Microbiol       Date:  2016-09-09       Impact factor: 5.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.